CN1589805A - Composition for treating tumour - Google Patents
Composition for treating tumour Download PDFInfo
- Publication number
- CN1589805A CN1589805A CN 03135661 CN03135661A CN1589805A CN 1589805 A CN1589805 A CN 1589805A CN 03135661 CN03135661 CN 03135661 CN 03135661 A CN03135661 A CN 03135661A CN 1589805 A CN1589805 A CN 1589805A
- Authority
- CN
- China
- Prior art keywords
- cell
- compositions
- tumor
- treatment
- matrine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A composition in the form of intravenous injection, tablet, capsule, etc contains the general flavone extracted from seabuckthorn fruit 1-10 wt. portions and sophocarpidine (1-10 wt. portions). It can be used to treat cervix cancer, liver cancer, tongue cancer, lung cancer etc.
Description
Technical field
The present invention relates to medicine, particularly treat the compositions medicine of tumor.
Background technology
Fructus Hippophae is the Elaeangnaceae hippophae plant.Fructus Hippophae total flavones is the flavone compound that extracts from Fructus Hippophae, and flavone compound is present in the middle of each position of Fructus Hippophae.Can adopt water or water-pure method to extract Fructus Hippophae total flavones from Fructus Hippophae, supercritical methanol technology also can be used for extracting Fructus Hippophae total flavones from Fructus Hippophae in addition.The Fructus Hippophae total flavones that studies show that in the past has the effect of containment medicated porridge sample arteriosclerosis, reduction blood cholesterol levels.Fructus Hippophae total flavones also has contraction and the diastolic function that increases heart, has significantly to resist myocardial ischemia and anti-arrhythmia effect.
The Chinese medicine Radix Sophorae Flavescentis is the root of leguminous plant Radix Sophorae Flavescentis, and the alkaloid that contains in the Radix Sophorae Flavescentis has pharmacological actions such as certain antitumor action and antivirus action.
Summary of the invention
In view of above-mentioned, the object of the present invention is to provide a kind of new compositions for the treatment of tumor.
A kind of compositions for the treatment of tumor of the present invention includes the Fructus Hippophae total flavones and the matrine for the treatment of effective dose.
Above-mentioned Fructus Hippophae total flavones is that the flavone that extracts from hippophae plant is overall.Above-mentioned Fructus Hippophae total flavones is by extracting method well-known to those skilled in the art, as water alcohol method, and the overall mixture of all flavone compounds that from various Fructus Hippophaes, extract.Mainly contain isorhamnetin in the Fructus Hippophae total flavones, Quercetin, isorhamnetin-3-O-rhamniose, isorhamnetin-3-O-glycoside, Isorhamnetin-3-O-rhamnosylglucoside., isorhamnetin-3-O-galactoside, isorhamnetin-7-O-rhamnoside, Quercetin-3-O-galactoside, Quercetin-3-O-glycoside, Quercetin-7-O-rhamnoside etc.
Above-mentioned matrine is Radix Sophorae Flavescentis total alkaloids, matrine monomer, oxymatrine monomer or oxymatrine monomer and the monomeric mixture of matrine.Above-mentioned Radix Sophorae Flavescentis total alkaloids is meant from various Radix Sophorae Flavescentiss by extracting method well-known to those skilled in the art, the overall mixture of all alkaloid compounds that extract from various Radix Sophorae Flavescentiss.Radix Sophorae Flavescentis total alkaloids mainly contains matrine, oxymatrine, sophor-anol, Sophocarpine, Ba Puye alkali, Anagyrine etc.
The content that above-mentioned Fructus Hippophae total flavones and matrine measure by weight in this compositions is Fructus Hippophae total flavones 1～10, matrine 1～10.Better be Fructus Hippophae total flavones 1～3, matrine 1～3.Preferably Fructus Hippophae total flavones 3, matrine 1.
Compositions of the present invention is applicable to the treatment tumor, particularly is applicable to tumors such as treatment cervical cancer, hepatocarcinoma, tongue scale cancer, adenocarcinoma of lung.
The mechanism of combination treatment tumor of the present invention is as follows:
1, inducing apoptosis of tumour cell and differentiation:
The form and the growth curve that impose the tumor cell after this compositions are measured, and the result that detects of flow cytometer.This compositions can inducing tumor cell apoptosis and differentiation, thereby the effect that produces the treatment tumor.
2, the propagation that suppresses tumor cell
By
3H-TdR (
3The deoxythymidine acid of H labelling) mix the result that experiment and flow cytometer detect, this compositions can suppress the synthetic of DNA and can suppress the propagation of tumor cell.Be blocked at G0/G1 (0 phase of interval and 1 phase in the cell cycle) phase in the cell cycle through the tumor cell of this compositions-treated, the tumor cell ratio that enters division stage descends.
3, influence the tumor cell expression of gene
The gene expression of tumor cell has obvious variation before and after being applied this compositions.By the detection of flow cytometer, use this compositions after, the expression of the Bcl-2 of tumor cell, c-myc and c-ha-ras obviously reduces, the expression of P-53, Bax is simultaneously risen.The expression of c-myc and c-ha-ras is excessive to be formed with substantial connection with tumor, and bcl-2 is the gene that suppresses apoptosis of tumor cells.The p53 gene can promote apoptosis of tumor cells; The bax expression of gene rises also can promote the apoptosis of tumor cell.Three genes of bcl-2, c-myc and c-ha-ras are expressed reduction in the tumor cell that this compositions-treated is crossed, the expression ascension theory of p53, bax understands that this compositions can make tumor cell produce the differentiation apoptosis simultaneously.
The common use of Fructus Hippophae total flavones in the compositions of the present invention and matrine can reach the effect of treatment tumor by above three kinds of mechanism.And the common use of Fructus Hippophae total flavones and matrine can produce synergism, and only uses Fructus Hippophae total flavones separately or only uses matrine to compare separately, can more effective treatment tumor under identical dosage.
Treatment is for convenience used, and can use method known to those skilled in the art, this compositions is made the dosage form that is fit to use.Be prepared into venoclysis liquid such as this compositions being dissolved in appropriate solvent such as normal saline; Or this compositions is made powder add suitable vehicle and be prepared into peroral dosage form, as capsule, tablet etc.
In order to understand the present invention better, illustrate that with anti-tumor experiment in effect experiment and the animal body this compositions is to the tumor treatment effect below.
One, this compositions is to the effect experiment of oncotherapy.The content that measures by weight in this following compositions is Fructus Hippophae total flavones 3, matrine 1.
(1) this compositions is to the effect experiment of human cervical carcinoma cell (Hela cell).
Inoculating cell is with 2 * 10
5Individual/ml in the 25ml culture bottle, random packet dosing in second day, the treatment group adopts that to contain concentration be that the cell culture fluid of 20 these compositionss of μ g/ml is handled the Hela cell, negative control group is handled the Hela cell for adopting the culture fluid that does not contain this compositions.
1, cellular morphology:
Inoculating cell is with 2 * 10
5Individual/ml in the 25ml culture bottle, random packet dosing in second day, drug treating is observed under inverted microscope two days later.
The matched group tumor cell: dense arrangement, cell is rounded, and it is many to examine big kernel.
Treatment group tumor cell: arrange sparsely, cell is microscler or polygon, the cavity that occurs differing in size in the part cell.
2, cell growth measurement:
Adopt mtt assay (3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl bromination tetrazolium) to measure the growing state of Hela cell matched group and treatment group.
Tumor cell after this compositions-treated is compared with cellular control unit, and the cell growth is subjected to obvious inhibition.
3, dull and stereotyped colony forms experiment
Inoculating cell is with 2 * 10
5Individual/ml in the 25ml culture bottle, random packet dosing in second day, after drug treating is changed common culture fluid and is continued to cultivate 7 days with 500 cells of each plate two days later, through methanol fix, Giemsa dye (dyeing of Ji's nurse Sa).Counting colony sum and colony-forming efficiency.
| Matched group | The treatment group | |
| Hela cell colony formation rate | ????70％ | ????37％ |
Tumor cell after this compositions-treated is compared with cellular control unit, and the cell colony formation rate obviously reduces, and illustrates that tumor cell multiplication capacity after the Fructus Hippophae total flavones effect descends.
4,
3H-TdR (
3The deoxythymidine acid of H labelling) mix experiment
Drug treating added after 24 hours
3H-TdR (final concentration is 0.5 μ Ci/ml (μ Ci: microcurie)), digestion after 4 hours, and centrifugal back dissolved in distilled water cell adopts paper disk method to measure cpm (per minute umber of pulse) value of cell on liquid scintillation counter
| Matched group | The treatment group | |
| Hela cell cpm value | ???3619 | ???1292 |
Tumor cell after this compositions-treated is compared with cellular control unit,
3H-TdR mixes obviously less.The synthetic decline of tumor cell DNA after the effect of this compositions is described, the growth of tumor cell is suppressed.
5, flow cytometer testing result
| Cell cycle distribution (%) | Apoptosis rate (%) | Gene expression mark rate (%) | ||||||||
| ?G0/G1 | ????S | ??G2+M | ??Bcl-2 | ??c-myc | ???Bax | ??Ha-ras | ??P-53 | ??c-fos | ||
| Matched group | ??65.3 | ???25.1 | ???9.6 | ???4.4 | ???26.5 | ???28.8 | ???46.1 | ???58.2 | ??25.3 | ??30.1 |
| The treatment group | ??85 | ???7.6 | ???7.4 | ???11.2 | ???10.5 | ???24.2 | ???78.1 | ???20.2 | ??27.4 | ??19.4 |
Annotate: G0/G1: 0 phase of interval and 1 phase in the cell cycle.
S: the DNA synthesis stage in the cell cycle.
G2+M:G2 is 2 phases of interval in the cell cycle, and M is the division stage in the cell cycle.
Tumor cell after this compositions-treated is compared with cellular control unit, and the ratio that tumor cell is in the G0/G1 phase in the cell cycle rises, and the tumor cell ratio that is in the G2+M phase descends.The tumor cell ratio of division stage descends, and represents that this compositions has reduced the division and proliferation speed of tumor.Obviously risen by the apoptosis of tumor cells rate after the effect of this compositions simultaneously, gene expression changes, and differentiation degree raises.
6, conclusion
Hela cell (human cervical carcinoma cell) is after this compositions-treated, cellular morphology changes, propagation is slack-off, colony-forming efficiency reduces,
3H-TdR mixes minimizing, cell cycle distribution change, the change of gene expression rate, apoptosis rate increase.Illustrate that this compositions makes Hela cell differentiation apoptosis, and reduce the DNA synthesis rate and the multiplication capacity of Hela cell, reach the effect of treatment cervical cancer.
(2) this compositions is to the effect experiment of people's tongue squamous cell carcinoma (Tca-8113 cell).
Inoculating cell is with 2 * 10
5Individual/ml in the 25ml culture bottle, random packet dosing in second day, the treatment group adopts that to contain concentration be that the cell culture fluid of 20 these compositionss of μ g/ml is handled the Tca-8113 cell, negative control group is handled the Tca-8113 cell for adopting the culture fluid that does not contain this compositions.
1, cellular morphology:
Inoculating cell is with 2 * 10
5Individual/ml in the 25ml culture bottle, random packet dosing in second day, drug treating is observed under inverted microscope two days later.
The matched group tumor cell: dense arrangement, cell is rounded, and it is many to examine big kernel.
Treatment group tumor cell: arrange sparsely, cell is microscler or polygon, the cavity that occurs differing in size in the part cell.
2, cell growth measurement:
Adopt mtt assay to measure the growing state of Tca-8113 cell matched group and treatment group.
Tumor cell after this compositions-treated is compared with cellular control unit, and the cell growth is subjected to obvious inhibition.
3, dull and stereotyped colony forms experiment
Inoculating cell is with 2 * 10
5Individual/ml in the 25ml culture bottle, random packet dosing in second day, after drug treating is changed common culture fluid and is continued to cultivate 7 days with 500 cells of each plate two days later, through methanol fix, Giemsa dye (dyeing of Ji's nurse Sa).Meter colony sum and colony-forming efficiency.
| Matched group | The treatment group | |
| Tca-8113 cell colony formation rate | ???74％ | ???46％ |
Tumor cell after this compositions-treated is compared with cellular control unit, and the cell colony formation rate obviously reduces, and illustrates that tumor cell multiplication capacity after the effect of this compositions descends.
4,
3H-TdR mixes experiment
Drug treating added after 24 hours
3H-TdR (final concentration is 0.5gCi/ml), digestion after 4 hours, centrifugal back dissolved in distilled water cell adopts paper disk method to measure the cpm value of cell on liquid scintillation counter
| Matched group | The treatment group | |
| Tca-8113 cell cpm value | ????4319 | ????3373 |
Tumor cell after this compositions-treated is compared with cellular control unit,
3H-TdR mixes obviously less.The synthetic decline of tumor cell DNA after the effect of this compositions is described, the growth of tumor cell is suppressed.
5, flow cytometer testing result
| Cell cycle distribution (%) | Apoptosis rate (%) | Gene expression mark rate (%) | ||||||||
| ?G0/G1 | ???S | ??G2+M | ??Bcl-2 | ?c-myc | ??bax | ?Ha-ras | ?c-fos | ?P-53 | ||
| Matched group | ?64.4 | ??25.2 | ??10.4 | ??6.8 | ??41.7 | ?34.9 | ??16.0 | ?31.3 | ?11.7 | ?24.0 |
| The treatment group | ??85 | ??7.1 | ???7.7 | ??15.5 | ??18.7 | ?25 | ??19.5 | ?20.2 | ?11.3 | ?37.1 |
Tumor cell after this compositions-treated is compared with cellular control unit, and the G0/G1 phase ratio that tumor cell is in the cell cycle rises, and the tumor cell ratio that is in the G2+M phase descends.The tumor cell ratio of division stage descends, and represents that this compositions has reduced the division and proliferation speed of tumor.Obviously risen by the apoptosis of tumor cells rate after the effect of this compositions simultaneously, gene expression changes, and differentiation degree raises.
6, conclusion
Tea-8113 cell (people's tongue squamous cell carcinoma) is after this compositions-treated, cellular morphology changes, propagation is slack-off, colony-forming efficiency reduces,
3H-TdR mixes minimizing, cell cycle distribution change, the change of gene expression rate, apoptosis rate increase.Illustrate that this compositions makes Tea-8113 cell differentiation apoptosis, and reduce the DNA synthesis rate and the multiplication capacity of Tca-8113 cell, reach the effect of treatment tongue scale cancer.
(3) this compositions is to the effect experiment of human liver cancer cell (SMMC-7721 cell).
Inoculating cell is with 2 * 10
5Individual/ml is in the 25ml culture bottle, random packet dosing in second day, the treatment group adopts that to contain concentration be that the cell culture fluid of 20 these compositionss of μ g/ml comes treatment S MMC-7721 cell, and negative control group is for adopting the culture fluid treatment S MMC-7721 cell that does not contain this compositions.
1, cellular morphology:
Inoculating cell is with 2 * 10
5Individual/ml in the 25ml culture bottle, random packet dosing in second day, drug treating is observed under inverted microscope two days later.
The matched group tumor cell: dense arrangement, cell is rounded, and it is many to examine big kernel.
Treatment group tumor cell: arrange sparsely, cell is microscler or polygon, the cavity that occurs differing in size in the part cell.
2, cell growth measurement:
Adopt mtt assay to measure the growing state of SMMC-7721 cell matched group and treatment group.
Tumor cell after this compositions-treated is compared with cellular control unit, and the cell growth is subjected to obvious inhibition.
3, dull and stereotyped colony forms experiment
Inoculating cell is with 2 * 10
5Individual/ml in the 25ml culture bottle, random packet dosing in second day, after drug treating is changed common culture fluid and is continued to cultivate 7 days with 500 cells of each plate two days later, through methanol fix, Giemsa dye (dyeing of Ji's nurse Sa).Counting colony sum and colony-forming efficiency.
| Matched group | The treatment group | |
| SMMC-7721 cell colony formation rate | ???53％ | ???32％ |
Tumor cell after this compositions-treated is compared with cellular control unit, and the cell colony formation rate obviously reduces, and illustrates that tumor cell multiplication capacity after the effect of this compositions descends.
4,
3H-TdR mixes experiment
Drug treating added after 24 hours
3H-TdR (final concentration is 0.5 μ Ci/ml), digestion after 4 hours, centrifugal back dissolved in distilled water cell adopts paper disk method to measure the cpm value of cell on liquid scintillation counter
| Matched group | The treatment group | |
| SMMC-7721 cell cpm value | ??3686 | ??1849 |
Tumor cell after this compositions-treated is compared with cellular control unit,
3H-TdR mixes obviously less.The synthetic decline of tumor cell DNA after the effect of this compositions is described, the growth of tumor cell is suppressed.
5, flow cytometer testing result
| Cell cycle distribution (%) | Gene expression mark rate (%) | ||||||
| ??G0/G1 | ????S | ?G2+M | ?Bcl-2 | ??Ha-ras | ?c-fos | ??P-53 | |
| Matched group | ????83 | ????9 | ??7.5 | ??32.8 | ???30.6 | ??21 | ???25 |
| The treatment group | ????86 | ??6.7 | ????6.8 | ??12.3 | ??16.8 | ??17.5 | ??26.7 |
Tumor cell after this compositions-treated is compared with cellular control unit, and the G0/G1 phase ratio that tumor cell is in the cell cycle rises, and the tumor cell ratio that is in the G2+M phase descends.The tumor cell ratio of division stage descends, and represents that this compositions has reduced the division and proliferation speed of tumor.Changed by the tumor cell gene expression after the effect of this compositions simultaneously, differentiation degree raises.
6, conclusion
SMMC-7721 cell (human liver cancer cell) is after this compositions-treated, cellular morphology changes, propagation is slack-off,
3H-TdR mixes minimizing, the gene expression rate changes.Illustrate that this compositions rises the SMMC-7721 cell differentiation, and reduce the DNA synthesis rate and the multiplication capacity of SMMC-7721 cell, reach the effect of treatment hepatocarcinoma.
(4) this compositions is to the effect experiment of human lung adenocarcinoma cell (YTMLC-90 cell).
Inoculating cell is with 2 * 10
5Individual/ml in the 25ml culture bottle, random packet dosing in second day, the treatment group adopts that to contain concentration be that the cell culture fluid of 20 these compositionss of μ g/ml is handled the YTMLC-90 cell, negative control group is handled the YTMLC-90 cell for adopting the culture fluid that does not contain this compositions.
1, cellular morphology:
Inoculating cell is with 2 * 10
5Individual/ml in the 25ml culture bottle, random packet dosing in second day, drug treating is observed under inverted microscope two days later.
The matched group tumor cell: dense arrangement, cell is rounded, and it is many to examine big kernel.
Treatment group tumor cell: arrange sparsely, cell is microscler or polygon, the cavity that occurs differing in size in the part cell.
2, cell growth measurement:
Adopt mtt assay to measure the growing state of YTMLC-90 cell matched group and smelting treatment group.
Tumor cell after this compositions-treated is compared with cellular control unit, and the cell growth is subjected to obvious inhibition.
3, dull and stereotyped colony forms experiment
Inoculating cell is with 2 * 10
5Individual/ml in the 25ml culture bottle, random packet dosing in second day, after drug treating is changed common culture fluid and is continued to cultivate 7 days with 500 cells of each plate two days later, through methanol fix, Giemsa dye (dyeing of Ji's nurse Sa).Meter colony sum and colony-forming efficiency.
| Matched group | The treatment group | |
| YTMLC-90 cell colony formation rate | ????31.5％ | ????16％ |
Tumor cell after this compositions-treated is compared with cellular control unit, and the cell colony formation rate obviously reduces, and illustrates that tumor cell multiplication capacity after the effect of this compositions descends.
4,
3H-TdR mixes experiment
Drug treating added after 24 hours
3H-TdR (final concentration is 0.5gCi/ml), digestion after 4 hours, centrifugal back dissolved in distilled water cell adopts paper disk method to measure the cpm value of cell on liquid scintillation counter
| Matched group | The treatment group | |
| YTMLC-90 cell cpm value | 5795 | ?2452 |
Tumor cell after this compositions-treated is compared with cellular control unit,
3H-TdR mixes obviously less.The synthetic decline of tumor cell DNA after the effect of this compositions is described, the growth of tumor cell is suppressed.
5, flow cytometer testing result
| Cell cycle distribution (%) | Apoptosis rate (%) | Gene expression mark rate (%) | ||||||||
| ?G0/G1 | ???S | ??G2+M | ??Bcl-2 | ??c-myc | ??bax | ??Ha-ras | ??c-fos | ??P-53 | ||
| Matched group | ?81.5 | ??10.2 | ??8.3 | ??4.7 | ??28.8 | ??31.8 | ??11.3 | ??25.4 | ??29.1 | ??26.8 |
| The treatment group | ?83.8 | ??7.1 | ??9.1 | ??14.9 | ??24.3 | ??28.9 | ??19.5 | ??18.9 | ??13.3 | ??26.8 |
Obviously risen by the apoptosis of tumor cells rate after the effect of this compositions, gene expression changes, and differentiation degree raises.
6, conclusion
YTMLC-90 cell (human lung adenocarcinoma cell) is after this compositions-treated, cellular morphology changes, propagation is slack-off, colony-forming efficiency reduces,
3H-TdR mixes minimizing, the change of gene expression rate, apoptosis rate increase.Illustrate that this compositions makes YTMLC-90 cell differentiation apoptosis, reach the effect of treatment adenocarcinoma of lung.
Two, this compositions is to anti-tumor experiment in the animal body of oncotherapy.The content that measures by weight in this following compositions is Fructus Hippophae total flavones 3, matrine 1.
Body weight 18～22 gram mices, male and female half and half.20 of every treated animals, it is identical with sex ratio that each organizes number of elements.Rat liver cancer H22 cell dilution becomes 1 * 10
7/ ml, every Corium Mus is injected oncocyte liquid 0.2ml down.Be divided into two group with mice next day.The isopyknic normal saline of blank group subcutaneous injection, this compositions of experimental group subcutaneous injection 20mg/kg.After the administration 5 days, put to death mice, weighing mice body weight and tumor are heavy.The results are shown in following table.
| Medicine | The mice number of elements | Mice body weight mean change at the whole story | The average tumor of mice is heavy | |
| Matched group | Normal saline | 20 | Increase by 1.1 grams | 1.6 gram |
| Experimental group | This compositions | 20 | Increase by 4.2 grams | 0.8 gram |
Experiment showed, that this compositions has the effect that suppresses the animal tumor growth in vivo.
In sum:, illustrate that this compositions can make form change, the gene expression rate of tumor cell change differentiation degree and rise, and can also make the apoptosis rate of tumor cell increase, and reduce the growing multiplication speed of tumor cell from above experimental result.Therefore, can draw the present invention and have following advantage.
One, the present invention has opened up new application to Fructus Hippophae total flavones and matrine, as the medicine of preparation treatment tumor.
Two, Drug therapy tumor effect of the present invention is good, and is all effective to kinds of tumor cells.Side effect when the treatment tumor is very little, and this compositions of therapeutic dose is to the not influence of normal cellular morphology function.And Fructus Hippophae total flavones and matrine can produce synergism, and both share the more effective treatment tumor of the dosage Fructus Hippophae total flavones more identical than independent use, the more effective treatment tumor of also identical than independent use dosage matrine.
Three, Fructus Hippophae total flavones and matrine raw material sources are extensive, cheap, and this compositions can be made into multiple dosage forms such as venoclysis agent, oral agents, and peroral dosage form can be tablet, capsule etc.
Below, the invention will be further described for reuse embodiment.The present invention can be illustrated with following embodiment, but is not limited in following examples.
The specific embodiment
Embodiment 1.
A kind of each embodiment such as table one for the treatment of the composition of medicine of tumor of the present invention.Take by weighing each component consumption in this compositions by table one, add the 1000ml normal saline, 30 ℃ of heating in water bath are dissolved in the normal saline each component fully.Solution disinfection filters the back fill, makes this compositions venoclysis liquid.Press dosage venoclysis when using as 5mg/kg/ days.
Table one
| The embodiment sequence number | Fructus Hippophae total flavones (mg) | Matrine (mg) | ||||
| Radix Sophorae Flavescentis total alkaloids | The matrine monomer | The oxymatrine monomer | Matrine monomer and oxymatrine monomer mixture | |||
| The matrine monomer | The oxymatrine monomer | |||||
| ??1-01 | ????182 | ????18 | ||||
| ??1-02 | ????180 | ????20 | ||||
| ??1-03 | ????160 | ????40 | ||||
| ??1-04 | ????140 | ????60 | ||||
| ??1-05 | ????120 | ????80 | ||||
| ??1-06 | ????100 | ????100 | ||||
| ??1-07 | ????80 | ????120 | ||||
| ??1-08 | ????60 | ????140 | ||||
| ??1-09 | ????40 | ????160 | ||||
| ??1-10 | ????20 | ????180 | ||||
| ??1-11 | ????18 | ????182 | ||||
| ??1-12 | ????182 | ????17 | ????1 | |||
| ??1-13 | ????180 | ????18 | ????2 | |||
| ??1-14 | ????160 | ????25 | ????15 | |||
| ??1-15 | ????150 | ????30 | ????20 | |||
| ??1-16 | ????120 | ????50 | ????30 | |||
| ??1-17 | ????100 | ????60 | ????40 | |||
| ??1-18 | ????80 | ????60 | ????60 | |||
| ??1-19 | ????60 | ????50 | ????90 | |||
| ??1-20 | ????40 | ????40 | ????120 | |||
| ??1-21 | ????20 | ????30 | ????150 | |||
| ??1-22 | ????18 | ????12 | ????170 | |||
| ??1-23 | ????182 | ????18 | ||||
| ??1-24 | ????180 | ????20 | ||||
| ??1-25 | ????160 | ????40 | ||||
| ??1-26 | ????140 | ????60 | ||||
| ??1-27 | ????120 | ????80 | ||||
| ??1-28 | ????100 | ????100 | ||||
| ??1-29 | ????80 | ????120 | ||||
| ??1-30 | ????60 | ????140 | ||||
| ??1-31 | ????40 | ????160 | ||||
| ??1-32 | ????20 | ????180 | ||||
| ??1-33 | ????18 | ????182 | ||||
| ??1-34 | ????182 | ????18 | ||||
| ??1-35 | ????180 | ????20 | ||||
| ??1-36 | ????160 | ????40 | ||||
| ??1-37 | ????140 | ????60 | ||||
| ??1-38 | ????120 | ????80 | ||||
| ??1-39 | ????100 | ????100 | ||||
| ??1-40 | ????80 | ????120 | ||||
| ??1-41 | ????60 | ????140 | ||||
| ??1-42 | ????40 | ????160 | ||||
| ??1-43 | ????20 | ????180 | ||||
| ??1-44 | ????18 | ????182 |
Embodiment 2
A kind of each embodiment such as table two for the treatment of the composition of medicine of tumor of the present invention.Take by weighing each component consumption in this compositions by table two, with 250g dry starch mix homogeneously.Powder is crossed 120 mesh sieves twice, fully mix homogeneously.Be filled in the capsulae vacuus respectively then.Make 1000 Fructus Hippophae total flavoness and matrine composition capsule, each contains Fructus Hippophae total flavones and matrine composition 50mg.
Table two
| The embodiment sequence number | Fructus Hippophae total flavones (mg) | Matrine (mg) | ||||
| Radix Sophorae Flavescentis total alkaloids | The matrine monomer | The oxymatrine monomer | Matrine monomer and oxymatrine monomer mixture | |||
| The matrine monomer | The oxymatrine monomer | |||||
| ?2-01 | ????46 | ????4 | ||||
| ?2-02 | ????45 | ????5 | ||||
| ?2-03 | ????40 | ????10 | ||||
| ?2-04 | ????35 | ????15 | ||||
| ?2-05 | ????30 | ????20 | ||||
| ?2-06 | ????25 | ????25 | ||||
| ?2-07 | ????20 | ????30 | ||||
| ?2-08 | ????15 | ????35 | ||||
| ?2-09 | ????10 | ????40 | ||||
| ?2-10 | ????5 | ????45 | ||||
| ?2-11 | ????4 | ????46 | ||||
| ?2-12 | ????46 | ????3 | ????1 | |||
| ?2-13 | ????45 | ????4 | ????1 | |||
| ?2-14 | ????40 | ????9 | ????1 | |||
| ?2-15 | ????37 | ????12 | ????1 | |||
| ?2-16 | ????30 | ????15 | ????5 | |||
| ?2-17 | ????25 | ????15 | ????10 | |||
| ?2-18 | ????20 | ????15 | ????15 | |||
| ?2-19 | ????15 | ????15 | ????20 | |||
| ?2-20 | ????13 | ????7 | ????30 | |||
| ?2-21 | ????5 | ????5 | ????40 | |||
| ?2-22 | ????4 | ????3 | ????43 | |||
| ?2-23 | ????46 | ????4 | ||||
| ?2-24 | ????45 | ????5 | ||||
| ?2-25 | ????40 | ????10 | ||||
| ?2-26 | ????37 | ????13 | ||||
| ?2-27 | ????30 | ????20 | ||||
| ?2-28 | ????25 | ????25 | ||||
| ?2-29 | ????20 | ????30 | ||||
| ?2-30 | ????15 | ????35 | ||||
| ?2-31 | ????10 | ????40 | ||||
| ?2-32 | ????5 | ????45 | ||||
| ?2-33 | ????4 | ????46 | ||||
| ?2-34 | ????46 | ????4 | ||||
| ?2-35 | ????45 | ????5 | ||||
| ?2-36 | ????40 | ????10 | ||||
| ?2-37 | ????37 | ????13 | ||||
| ?2-38 | ????30 | ????20 | ||||
| ?2-39 | ????25 | ????25 | ||||
| ?2-40 | ????20 | ????30 | ||||
| ?2-41 | ????15 | ????35 | ||||
| ?2-42 | ????10 | ????40 | ||||
| ?2-43 | ????5 | ????45 | ||||
| ?2-44 | ????4 | ????46 |
Embodiment 3
A kind of each embodiment such as table three for the treatment of the composition of medicine of tumor of the present invention.Take by weighing each component consumption in this compositions by table three, mix by the equivalent method of progressively increasing with dry starch, mix homogeneously sieves.Then with the dextrin mix homogeneously.Add an amount of ethanol, granulate 50 ℃ of dryings by 16 mesh sieves.Dry granular is crossed 16 mesh sieves, adds magnesium stearate, tabletting behind the mixing.Be pressed into 1000, every contains Fructus Hippophae total flavones and matrine composition 50mg.
Table three
| The embodiment sequence number | Fructus Hippophae total flavones (mg) | Matrine (mg) | ||||
| Radix Sophorae Flavescentis total alkaloids | The matrine monomer | The oxymatrine monomer | Matrine monomer and oxymatrine monomer mixture | |||
| The matrine monomer | The oxymatrine monomer | |||||
| ??3-01 | ????46 | ????4 | ||||
| ??3-02 | ????45 | ????5 | ||||
| ??3-03 | ????40 | ????10 | ||||
| ??3-04 | ????35 | ????15 | ||||
| ??3-05 | ????30 | ????20 | ||||
| ??3-06 | ????25 | ????25 | ||||
| ??3-07 | ????20 | ????30 | ||||
| ??3-08 | ????15 | ????35 | ||||
| ??3-09 | ????10 | ????40 | ||||
| ??3-10 | ????5 | ????45 | ||||
| ?3-11 | ????4 | ????46 | ||||
| ??3-12 | ????46 | ????3 | ????1 | |||
| ??3-13 | ????45 | ????4 | ????1 | |||
| ??3-14 | ????40 | ????9 | ????1 | |||
| ??3-15 | ????37 | ????12 | ????1 | |||
| ??3-16 | ????30 | ????15 | ????5 | |||
| ??3-17 | ????25 | ????15 | ????10 | |||
| ??3-1?8 | ????20 | ????15 | ????1?5 | |||
| ??3-19 | ????15 | ????15 | ????20 | |||
| ??3-20 | ????13 | ????7 | ????30 | |||
| ??3-21 | ????5 | ????5 | ????40 | |||
| ??3-22 | ????4 | ????3 | ????43 | |||
| ??3-23 | ????46 | ????4 | ||||
| ??3-24 | ????45 | ????5 | ||||
| ??3-25 | ????40 | ????10 | ||||
| ??3-26 | ????37 | ????13 | ||||
| ??3-27 | ????30 | ????20 | ||||
| ??3-28 | ????25 | ????25 | ||||
| ??3-29 | ????20 | ????30 | ||||
| ??3-30 | ????15 | ????35 | ||||
| ??3-31 | ????10 | ????40 | ||||
| ??3-32 | ????5 | ????45 | ||||
| ??3-33 | ????4 | ????46 | ||||
| ??3-34 | ????46 | ????4 | ||||
| ??3-35 | ????45 | ????5 | ||||
| ?3-36 | ????40 | ????10 | ||||
| ??3-37 | ????37 | ????13 | ||||
| ??3-38 | ????30 | ????20 | ||||
| ??3-39 | ????25 | ????25 | ||||
| ??3-40 | ????20 | ????30 | ||||
| ??3-41 | ????15 | ????35 | ||||
| ?3-42 | ????10 | ????40 | ||||
| ?3-43 | ????5 | ????45 | ||||
| ?3-44 | ????4 | ????46 |
Claims (10)
1, a kind of compositions for the treatment of tumor is characterized in that comprising Fructus Hippophae total flavones and matrine.
2,, it is characterized in that said Fructus Hippophae total flavones is that the flavone that extracts is overall from hippophae plant according to said a kind of compositions for the treatment of tumor in the claim 1.
3,, it is characterized in that said matrine is a kind of in Radix Sophorae Flavescentis total alkaloids, matrine monomer, oxymatrine monomer or oxymatrine monomer and the monomeric mixture of matrine according to said a kind of compositions for the treatment of tumor in the claim 1.
4, according to said a kind of compositions for the treatment of tumor in the claim 1,2 or 3, it is characterized in that the content that measures by weight: Fructus Hippophae total flavones 1～10, matrine 1～10.
5, according to said a kind of compositions for the treatment of tumor in the claim 1,2 or 3, it is characterized in that the content that measures by weight: Fructus Hippophae total flavones 1～3, matrine 1～3.
6, according to said a kind of compositions for the treatment of tumor in the claim 1,2 or 3, it is characterized in that the content that measures by weight: Fructus Hippophae total flavones 3, matrine 1.
7, according to claim 1,2 or 3 described a kind of compositionss for the treatment of tumor, it is characterized in that it being venoclysis agent or oral agents.
8, a kind of compositions for the treatment of tumor according to claim 4 is characterized in that it being venoclysis agent or oral agents.
9, a kind of compositions for the treatment of tumor according to claim 5 is characterized in that it being venoclysis agent or oral agents.
10, a kind of compositions for the treatment of tumor according to claim 6 is characterized in that it being venoclysis agent or oral agents.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03135661 CN1589805A (en) | 2003-08-25 | 2003-08-25 | Composition for treating tumour |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03135661 CN1589805A (en) | 2003-08-25 | 2003-08-25 | Composition for treating tumour |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1589805A true CN1589805A (en) | 2005-03-09 |
Family
ID=34597190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03135661 Pending CN1589805A (en) | 2003-08-25 | 2003-08-25 | Composition for treating tumour |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1589805A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101971978A (en) * | 2010-07-26 | 2011-02-16 | 山西振东五和健康食品股份有限公司 | Nutrient porridge based on malignant tumor radiotherapy patient |
| WO2013143412A1 (en) * | 2012-03-29 | 2013-10-03 | 武汉华大药业有限公司 | Pharmaceutical compositions |
| CN111035758A (en) * | 2018-10-11 | 2020-04-21 | 江苏康缘药业股份有限公司 | Pharmaceutical composition, application thereof, sterile container and kit |
-
2003
- 2003-08-25 CN CN 03135661 patent/CN1589805A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101971978A (en) * | 2010-07-26 | 2011-02-16 | 山西振东五和健康食品股份有限公司 | Nutrient porridge based on malignant tumor radiotherapy patient |
| WO2013143412A1 (en) * | 2012-03-29 | 2013-10-03 | 武汉华大药业有限公司 | Pharmaceutical compositions |
| CN111035758A (en) * | 2018-10-11 | 2020-04-21 | 江苏康缘药业股份有限公司 | Pharmaceutical composition, application thereof, sterile container and kit |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1484525A (en) | Combinations of drugs (E. G chlorpromazine and pentamidine) for the treatment of neoplastic disorders | |
| Bailey-Downs et al. | Development and characterization of a preclinical model of breast cancer lung micrometastatic to macrometastatic progression | |
| CN1729002A (en) | Exemestane as chemopreventing agent | |
| CN1192775C (en) | Prophylactic and therapeutic use of oltipraz as antifibrotic and anticirrhotic agent in liver and pharmaceutical composition contg. oltipraz | |
| CN1198599C (en) | Long time drug-sustained release preparation | |
| CN1772262A (en) | Broad-spectrum cancer-treating Chinese medicine prepn and its prepn process | |
| CN1681489A (en) | Combination of chemotherapeutic drugs for increasing antitumor activity | |
| CN1589805A (en) | Composition for treating tumour | |
| CN1691943A (en) | Cancer treatment with go6976 and its related compounds | |
| CN1895337A (en) | Pharmaceutical use of Tangshen and Milkvetch root composition for improving late tumor patient life quality | |
| CN1895244A (en) | Medicinal composition for preventing and treating cancer diseases | |
| US11951178B2 (en) | Methods for treating subjects suffering from acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles | |
| CN1279980C (en) | Anti solid tumor medicine composition | |
| CN1518986A (en) | Application of isorhamnetin and its ramification in medication for treating tumor | |
| CN1265832C (en) | External used medicines for Hong Kong foot and tinea manuum | |
| CN1281593C (en) | Immune regulation and biological therapeutic function of benzo-isoselenazole derivatives | |
| CN1286526C (en) | Anti-cancer medicine composition | |
| CN1302786C (en) | Chinese medicine soft capsule for treating mastoncus and its preparation method | |
| CN1957923A (en) | A kind of controlled release injection of carried fluorouracil and synergis | |
| CN1990031A (en) | Crude drug for preventing tumor metastasis | |
| CN1056748C (en) | Use of bolbostemmaoside A to prepare medicine for treatment of leukemia | |
| CN1117098C (en) | Cancer suppressing action of antisense nucleic acid to leukemia gene of bursa-dependent lymphocyte | |
| CN1738533A (en) | Methods for inhibiting cancer and scar formation | |
| CN1092680A (en) | The Chinese medicine anticancer powdered injection | |
| CN1299773C (en) | Anti-cancer medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| AD01 | Patent right deemed abandoned | ||
| C20 | Patent right or utility model deemed to be abandoned or is abandoned |